33098-10-1

Basic information

• Product Name: 4,5-DICHLORO-2-ETHYL-3(2H)-PYRIDAZINONE
• Synonyms: 4,5-DICHLORO-2-ETHYL-3(2H)-PYRIDAZINONE;4,5-dichloro-2-ethyl-2,3-dihydropyridazin-3-one
• CAS NO: 33098-10-1
• Molecular Formula: C₆H₆Cl₂N₂O
• Molecular Weight: 193.03
• Mol File: 33098-10-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,5-DICHLORO-2-ETHYL-3(2H)-PYRIDAZINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-DICHLORO-2-ETHYL-3(2H)-PYRIDAZINONE(33098-10-1)
• EPA Substance Registry System: 4,5-DICHLORO-2-ETHYL-3(2H)-PYRIDAZINONE(33098-10-1)

Safety Data

• Hazardous Substances Data: 33098-10-1(Hazardous Substances Data)

Upstream product

• 932-22-9 4,5-dichloro-2H-pyridazin-3-one 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 

Downstream Products

• 98796-15-7 4-Chloro-2-ethyl-5-methylamino-2H-pyridazin-3-one 
• 98796-05-5 5-Chloro-2-ethyl-4-methylamino-2H-pyridazin-3-one 
• 272120-83-9 7-(4-benzoyloxybutyl)-4-chloro-5-cyano-2-ethyl-7H-pyrrolo[2,3-c]pyridazin-3(2H)-one 
• 1027344-32-6 ethyl 2-(4'-chloro-2'-ethyl-3'-oxopyridazin-5'-yl)-2-(4''-nitrophenyl)propanoate 

Relevant articles and documents

New Design Rules for Developing Potent Cell-Active Inhibitors of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition

The nucleosome remodeling factor (NURF) alters chromatin accessibility through interactions with its largest subunit,the bromodomain PHD finger transcription factor BPTF. BPTF is overexpressed in several cancers and is an emerging anticancer target. Targeting the BPTF bromodomain presents a potential strategy for its inhibition and the evaluation of its functional significance; however, inhibitor development for BPTF has lagged behind those of other bromodomains. Here we describe the development of pyridazinone-based BPTF inhibitors. The lead compound,BZ1, possesses a high potency (Kd= 6.3 nM) and >350-fold selectivity over BET bromodomains. We identify an acidic triad in the binding pocket to guide future designs. We show that our inhibitors sensitize 4T1 breast cancer cells to doxorubicin but not BPTF knockdown cells, suggesting a specificity to BPTF. Given the high potency and good physicochemical properties of these inhibitors, we anticipate that they will be useful starting points for chemical tool development to explore the biological roles of BPTF.

IMIDAZOLES

The present invention relates to imidazole derivatives of the general formula wherein R1, R2, R3, and R4 are as defined in the specification and to pharmaceutically acceptable salts thereof. Compounds of formula I are metabotropic glutamate receptor antagonists. They can be used in the treatment or prevention of mGluR5 receptor mediated disorders.

Concurrent Alkylation-Methoxylation of 4,5-Dihalopyridazin-6-ones and Synthesis of 5-Halo-4-hydroxypyridazin-6-ones

1-Alkyl-5-halo-4-methoxypyridazin-6-ones were synthesized from 1-alkyl-4,5-dihalopyridazin-6-ones by the concurrent alkylation-methoxylation. 1-Alkyl-5-halo-4-hydroxypyridazin-6-ones were also prepared.